Pier Paolo Scaglioni Lab
The Scaglioni laboratory’s central goal is to identify cellular networks that are required for cancer maintenance. To enable this research, we integrate the use of advanced lipidomics, mouse cancer models, cancer cell lines, small molecule inhibitors, RNAi and CRISPR technologies. To identify mechanisms that mediate cancer maintenance, we chose to focus our efforts on cancer types that depend on their initiating oncogene. With this approach, we have identified several targetable cancer vulnerabilities. For instance, we identified focal adhesion kinase, XPOI nuclear export receptor and fatty acid metabolism as novel vulnerabilities of mutant KRAS lung cancer. These findings provided the rationale for several clinical trials (NCI identifiers: NCT01951690, NCT03095612, NCT02223247 and NCT03808558).